drugset
Drugs / SULANEMADLIN
last change Mar 2026 re-read 2 minutes ago

SULANEMADLIN

also known as ALRN-6924

Peptide targets MDM2 via inhibition

Developed for
acute myeloid leukemia · brain neoplasm · cancer · chemotherapy-induced toxicity · estrogen-receptor positive breast cancer · Her2-receptor negative breast cancer · leukemia · lymphoma
+5 more · metastatic malignant neoplasm · myelodysplastic syndrome · non-small cell lung carcinoma · peripheral T-cell lymphoma, not otherwise specified · small cell lung carcinoma
Investigated by
Aileron Therapeutics, Inc. · Cookies for Kids' Cancer · Dana-Farber Cancer Institute · M.D. Anderson Cancer Center · National Cancer Institute (NCI) · TeamConnor Childhood Cancer Foundation

Trials 6 · a red edge is where a trial was stopped

today NCT05622058 · Ph 1 NCT04022876 · Ph 1 NCT03725436 · Ph 1 NCT03654716 · Ph 1 NCT02909972 · Ph 1 NCT02264613 · Ph 1/2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT05622058 Jan → Feb 2023 chemotherapy-induced toxicity Aileron Therapeutics, Inc. Terminated No outcome recorded
Phase 1 NCT04022876 Sep 2019 → Jul 2022 non-small cell lung carcinoma, small cell lung carcinoma Aileron Therapeutics, Inc. Terminated No outcome recorded
Phase 1 NCT03725436 Jan 2019 → Mar 2026 Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, metastatic malignant neoplasm M.D. Anderson Cancer Center Completed No outcome recorded
Phase 1 NCT03654716 Nov 2018 → Jul 2023 brain neoplasm, leukemia, lymphoma Dana-Farber Cancer Institute Completed No outcome recorded
Phase 1 NCT02909972 Sep 2016 → Apr 2019 acute myeloid leukemia, myelodysplastic syndrome Aileron Therapeutics, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02264613 Oct 2014 → Mar 2020 cancer, peripheral T-cell lymphoma, not otherwise specified Aileron Therapeutics, Inc. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as SULANEMADLIN ChEMBL registry synonym — accepted as the source's own label CHEMBL5095209 ↗
Known as ALRN-6924 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02909972 ↗
5

NCT02264613 ↗

NCT05622058 ↗

NCT04022876 ↗

NCT03725436 ↗

NCT03654716 ↗
Action Inhibit “The MDM2 inhibitor ALRN-6924 induced a viral mimicry pathway” PMID 34230007 ↗ Dec 2021
Modality Peptide “ALRN-6924 is a stabilized cell-permeating peptide” NCT02264613 ↗
Route Intravenous “ALRN-6924 will be administered as an IV infusion” NCT02264613 ↗
Target MDM2 “ALRN-6924 is a stabilized cell-permeating peptide designed to disrupt the interaction between the p53 tumor suppressor protein and its predominant endogenous inhibitors, murine...” NCT02264613 ↗